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Abstract 
Maximin H5 is an anionic antimicrobial peptide from amphibians, which carries a C-terminal 
amide moiety, and was found to be moderately haemolytic (18 %). The α-helicity of the peptide 
was 42 % in the presence of lipid mimics of erythrocyte membranes and was found able to 
penetrate (10.8 mN m-1) and lyse these model membranes completely. In contrast, the 
deaminated peptide exhibited lower levels of haemolysis (11 %) and α-helicity (16 %) along 
with a reduced ability to penetrate (7.8 mN m-1) and lyse (55.2 %) lipid mimics of erythrocyte 
membranes. Taken with molecular dynamic simulations and theoretical analysis, these data 
suggest that native maximin H5 primarily exerts its haemolytic action via the formation of an 
oblique orientated α-helical structure and tilted membrane insertion. However, the C-terminal 
deamination of maximin H5 induces a loss of tilted α-helical structure, which abolishes the 
ability of the peptide’s N-terminal and C-terminal regions to H-bond and leads to a loss in 
haemolytic ability. Taken in combination, these observations strongly suggest that the C-
terminal amide moiety carried by maximin H5 is required to stabilise the adoption of membrane 
interactive tilted structure by the peptide. Consistent with previous reports, these data show 
that the efficacy of interaction and specificity of maximin H5 for membranes can be attenuated 
by sequence modification and may assist in the development of variants of the peptide with the 
potential to serve as anti-infectives.  
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Highlights 
• Maximin H5 (MH5) is an anionic antimicrobial peptide 
• MD simulations were used to study role of C-terminal amidation 
• C-terminal amidation moiety of MH5 is required to stabilise α-helical structure 
• Deaminated peptide exhibited low levels of haemolysis and peptide activity.  
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Introduction  
Antimicrobial peptides (AMPs) are ancient components of the innate immune systems that are 
found in creatures from across the eukaryotic kingdom and they possess potent activity against 
a wide spectrum of bacteria, viruses, fungi and parasites [1, 2]. In general, this activity involves 
membrane interaction [3, 4] and increasingly, it has been found that post-translational 
modifications (PTMs) play a role in optimising the efficacy and specificity of these 
mechanisms of action [5-9]. Most of the PTMs identified in AMPs are relatively infrequent in 
occurrence [6],  typically the phosphorylation of residues [1, 6, 10] and the chiral inversion of 
residues to produce D-amino acids [11-13]. However, two PTMs have been found to be 
ubiquitous amongst AMPs of eukaryotes [6] of which the first is the oxidation of cysteine 
residues to form disulphide bridges [14]. It is generally accepted that disulphide bridges play a 
major architectural role in the antimicrobial action of AMPs [6], primarily by maintaining the 
amphiphilic topography of the molecules and thereby their ability to interact with target 
membranes and kill host cells [5, 15]. This form of structural stabilization is also important for 
the therapeutic development of AMPs as seen with the cysteine knot architectures of cyclotides 
from plants [2, 16]. The exceptional stability of these peptides coupled to their high tolerance 
of residue substitutions [17] makes them potential candidates to serve as lead compounds in 
scenarios ranging from tumour imaging [18] to preventing the sexual transmission of HIV [19]. 
 
The second most common PTM found in AMPs is the introduction of C-terminal moieties, 
which have predominantly been identified in amphibians [6].  These fall into two major classes: 
the presence of either a Rana box [20] or an amide group [21]. The Rana box is found in the 
vast majority of Ranid frogs and consists of a C-terminal cyclic heptapeptide with a conserved 
disulphide bond [20, 22, 23]. This PTM occurs in AMPs such as gaegurins and palustrins and 
appears to play a role in facilitating the membrane affinity of these peptides by stabilising their 
C-terminal structure [20, 24]. In contrast, the importance of C-terminal amidation in the 
antimicrobial action of amphibian and other AMPs is far from clearly understood [25]. Most 
recently, a suite of homologous AMPs, maximin H1 to maximin H55, were identified in toads 
from the Bombina genus.  These AMPs all exhibited C-terminal amidation, clearly suggesting 
functional relevance [26-28]. Studies on synthetic AMPs have shown that C-terminal 
amidation can enhance antibacterial efficacy without increasing lytic ability thereby increasing 
the therapeutic potential of these peptides [29]. Given that maximin H5 from Bombina maxima 
has potent, narrow range, antibacterial activity [30], we have investigated the role of C-terminal 
amidation in the interactions of the peptide with erythrocyte membranes to help elucidate the 
suitability of the peptide for medical use.   
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Materials and Methods  
Reagents 
A synthetic homologue of maximin H5, MH5N (ILGPVLGLVSDTLDDVLGIL-CONH2), and 
its C-terminally deamidated isoform, MH5C (ILGPVLGLVSDTLDDVLGIL-COOH), were 
manufactured by Pepceuticals (Leicestershire, UK) by solid state synthesis and purified by 
HPLC to purity greater than 95 %.  Dimyristoyl phosphatidylcholine (DMPC) was supplied by 
Avanti Polar Lipids (Alabaster, Alabama) and used without further purification and analyzed 
using mass spectrometry (Figure S1).  All other reagents were supplied by SIGMA (UK) and 
VWR (UK) unless otherwise stated.  
 
The antibacterial assay of maximin H5 isoforms 
Cultures of E. coli, strain W3110, and Staphylococcus aureus, strain UL12, which had both 
been freeze-dried in 20 % (v/v) glycerol and stored at −80 °C, were used to inoculate 10 ml 
aliquots of sterile nutrient broth and incubated at 37 °C until the exponential phase was reached  
(OD = 0.6; λ = 600 nm).  The cell cultures were then centrifuged at 15000 × g at 4 °C for 15 
minutes using a bench top centrifuge.  The resulting pellet was washed three times in 25 % 
strength Ringer’s solution and then then re-suspended in 1 ml Ringer's solution.  1 ml aliquots 
of maximin H5 isoforms ranging from 0 µM to 1000 µM were prepared separately in 25 % 
strength Ringer’s solution by the double dilution method. 20 µl of each test bacterial suspension 
was added to separate 1 ml aliquots of peptide and incubated at 37 °C for 48 hrs. After 
incubation, each bacterial culture was streaked onto nutrient agar plates so as to create a six-
spoked star wheel and incubated at 37 °C for 12 h as previously described by Dennison et al. 
[31]. This method was carried out in triplicate.  The minimum inhibition concentration (MIC) 
was determined from the lowest final concentration of peptide at which no growth was 
observed during the predetermined period of incubation in any of the triplicate samples.  
 
The haemolytic ability of maximin H5 isoforms  
The haemolytic activity of MH5N and MH5C were investigated using fresh human red blood 
cells (3 ml), which were washed 3 times with phosphate buffered saline (PBS, pH 7.4) by 
centrifugation for 5 minutes at 1200 × g until the supernatant was clear.  Washed red blood 
cells were resuspended in PBS to a final volume of 20 ml.  Peptide solutions (10 µl) were added 
to a 190 µl suspension of washed red blood cells and incubated for 1h at 37 °C.  The samples 
were then centrifuged at 12000 × g for 5 minutes. The release of haemoglobin was monitored 
by diluting 100 µl of supernatant with 900 µl PBS and measuring the absorbance at 576 nm 
[APeptide].  For negative and positive controls, PBS buffer [APBS] and 0.1% Triton X-100 [ATriton] 
were used. These experiments were performed in quadruplicate and the mean percentage 
haemolysis calculated using the equation [32, 33]: 
𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 ℎ𝑃𝑃𝑃𝑃𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 =  �𝐴𝐴𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃� − [𝐴𝐴𝑃𝑃𝑃𝑃𝑃𝑃][𝐴𝐴𝑇𝑇𝑇𝑇𝑃𝑃𝑃𝑃𝑇𝑇𝑇𝑇] − [𝐴𝐴𝑃𝑃𝑃𝑃𝑃𝑃] × 100 
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Secondary structural analysis of maximin H5 isoforms  
Secondary structure analysis of MH5N and MH5C was performed using a J-815 
spectropolarimeter (Jasco, UK) at 20 °C, as previously described [34]. Samples were prepared 
by dissolving the peptides in phosphate buffered saline (PBS) and 2, 2, 2-trifluoroethanol / 
phosphate buffered saline (TFE / PBS; 50% v/v) to give a final peptide concentration of 60 μM 
in each case. Circular dichroism (CD) structural analysis was also performed with MH5N and 
MH5C in the presence of lipid. DMPC (19 mg ml−1) was dissolved in chloroform, dried under 
N2 gas before being vacuum-dried, and the resulting lipid film rehydrated using 1 × PBS (pH 
7.5) for an hour, or until the solution was no longer turbid. These samples were then freeze-
thawed 4 times, followed by extrusion 11 times with a 0.1 μm polycarbonate filter using an 
Avanti Polar Lipids mini-extruder apparatus. Peptide / lipid samples were prepared by adding 
stock peptide solution to a measured volume of lipid suspension to obtain the desired peptide: 
lipid molar ratio (1:100) before being mixed thoroughly.  Far UV (180 to 260 nm) CD spectra 
were recorded using 0.5 nm intervals, a bandwidth of 1 nm, a scan speed of 100 nm min−1 and 
a 10 mm path-length cell.  Four scans per sample were performed and averaged.  For secondary 
structure estimation, the CD spectra were deconvoluted using the CDSSTR algorithm (protein 
reference set 3) on the DichroWeb server [35-37].   
 
Lipid monolayer analysis of maximin H5 isoforms  
Lipid monolayers of DMPC were formed by dropping chloroformic solutions of the lipid onto 
a Tris buffer subphase (10 mM; pH 7.5) contained in an 80 ml 601M Langmuir Teflon trough 
(Biolin Scientific/KSV NIMA, UK).  Surface pressure (π) was measured using a Wilhelmy 
wire attached to a microbalance.  After spreading, the solvent was allowed to evaporate off the 
subphase surface over 30 minutes and the barriers were closed at a rate of 5 cm2 min-1 until a 
starting pressure of 30 mN m-1 was achieved, which is  equivalent to that of the outer leaflet of 
a cell membrane [38].  Monolayers were allowed to equilibrate for a further 30 minutes before 
MH5N and MH5C were injected into the subphase using an L-shaped Hamilton syringe 
without disruption of the monolayer.   
 
The lytic ability of maximin H5 isoforms  
DMPC (7.5 mg) was dissolved in chloroform and dried under N2 gas before being vacuum-
dried. The resulting lipid film was then hydrated with 1 ml of HEPES (5.0 mM; pH 7.5) 
containing calcein (70 mM).  The suspension was vortexed for 5 minutes and then sonicated 
for 30 minutes after which, the solution underwent 3 cycles of freeze-thawing.  Liposomes 
were extruded 11 times through a 0.1 µm polycarbonate filter using an Avanti polar lipids mini-
extruder apparatus.  Calcein entrapped vesicles were separated from free calcein by gel 
filtration using a Sephadex G75 column (Sigma Aldrich, UK) which was rehydrated overnight 
in HEPES (20 mM; pH 7.5), NaCl (150 mM) and EDTA (1.0 mM). The column was then 
eluted with HEPES (5 mM; pH 7.5).   
 
The calcein release assay was performed by combining 2 ml of HEPES (20 mM; pH 7.5), NaCl 
(150 mM) and EDTA (1.0 mM) with 20 µl of calcein vesicles. MH5N and MH5C (90 µM) 
were incubated with these vesicles and the fluorescence intensities of released calcein 
measured using an FP-6500 spectrofluorometer (Jasco, UK), with an excitation wavelength of 
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490 nm and emission wavelength of 520 nm.  Membrane lysis of 100 % was taken as the 
fluorescence induced by Triton × 100 (20 µl) when used to dissolve the vesicles. The 
percentage lysis achieved by MH5N and MH5C was then calculated relative to this standard. 
 
 
MD simulations of maximin H5 isoforms 
The conformational behaviour and lipid interactivity of MH5N and MH5C in the presence of 
DMPC membranes was examined by molecular dynamics calculations, as previously described 
[39]. Using peptide / lipid ratios of 3:128, models for MH5N and MH5C were assembled as 
canonical α-helices using AMBER tools 12 as previously described [39]. Simulations and 
analysis were performed using GROMACS and the GROMOS96 53a6 force field was used 
with the step descended method. Bilayer parameters were used from references and the simple 
point-charge (SPC) water model was used in all simulations. All structures were equilibrated 
at room temperature in water in the sequence: minimization, NVT and NPT simulations. The 
simulations in water were performed by solvating the peptide in a box: 6 nm × 6 nm × 6 nm 
with approximately 8000 water molecules. Counter-ions (Na+ Cl-) were added to the system to 
make it neutral.  The peptide was simulated with backbone atoms restrained in NVT and then 
NPT ensemble with pressure maintained at 1 atm by isotropic coupling to a Berendsen barostat 
and the temperature maintained at 303 °K. A free molecular dynamic simulation of 200 ns 
without restraint was performed at constant temperature, pressure and number of molecules 
(NPT ensemble). The membrane was simulated using a DMPC bilayer containing 128 lipid 
molecules in a box 7nm × 7  nm  ×  9.0  nm  (xyz box) with the bilayer normal being parallel 
to the z-axis. An equilibration run was 400 ns long at 303 °K in a box containing circa 10000 
water molecules. For both MH5N and MH5C, three peptide molecules were inserted into the 
box containing the solvated bilayer. An equilibration run of 2 ns was carried out for the peptide-
bilayer system with the position of the peptides restrained using harmonic restrains with 
constant force of 1.0  kJ-1 nm-2 per atom. The cut off for both van der Waals and Coulombic 
interactions was 1.2 nm. Berendsen temperature coupling was used at 303 °K and the water 
and the bilayer were coupled separately. A semi-isotropic Berendsen barometer was used. The 
main molecular dynamics simulation (no restraints) runs were performed at constant 
temperature, pressure and number of molecules.  
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Results  
The antibacterial assay of maximin H5 isoforms 
The antimicrobial activity of MH5N was tested and exhibited activity against S. aureus (MIC 
= 90 µM) but was found to be ineffective against E. coli, which is consistent with previous 
reports [30].  In contrast, MH5C was found to have a reduced capability to inactivate S. aureus 
(MIC = 180 µM) but was effective against E. coli (MIC = 180 µM). The antibacterial activity 
of both peptides is comparable with that of other anionic AMPs [1, 16] such as  Cn-AMP2 and 
Cn-AMP3 from the plant, Cocos nucifera [40], and GH- 1L, and GH-1D, from the toad, 
Bombina orientalis  [41].  
 
The haemolytic ability of maximin H5 isoforms  
The ability of MH5N and MH5C to interact with human erythrocytes was assayed and it was 
found that below concentrations of 25 µM, both peptides showed low, comparable haemolytic 
activity, which was < 12 %. Above 25 µM, MH5N became progressively more haemolytic than 
MH5C although both peptides remained moderately active towards erythrocytes, inducing 
between circa 15 % and 25 % lysis at peptide concentrations above 450 µM (Figure 1).  These 
data also showed that at its MLC for S. aureus (90 µM) MH5N exhibited haemolysis levels of 
20 % whilst at its MLC for both S. aureus and E. coli (180 µM) MH5C induced haemolysis 
levels of 12 %. 
 
Figure 1. The haemolytic ability of isoforms of maximin H5. Figure 1 shows the haemolytic 
activity of MH5N (Black) and MH5C (grey) towards human red blood cells. MH5N showed 
greater activity towards these cells than MH5C with these peptides inducing 20% and 12% 
lysis, respectively, at 90 µM, which is the reported antibacterial minimum inhibitory 
concentration (MIC) for maximin H5 [28, 39]. These experiments were performed in 
quadruplicate and error bars represent the standard deviation.  
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Secondary structural analysis of maximin H5 isoforms  
The conformational behaviour of MH5N and MH5C in different environments was 
investigated using CD spectroscopy. In aqueous solution, both peptides were not well folded 
with a maximum at 212 nm and a minimum at 195 nm (Figure 2). Analysis of these CD spectra 
showed that MH5N and MH5C both possessed < 10 % α-helical structure and were 
predominantly formed from random coil and β-type structures (Supplementary data, Table 1).  
A key step in the membrane interaction of AMPs involves the adoption of secondary structures 
in the anisotropic environment of the interface [29], which is often investigated using TFE, a 
lipophilic, membrane-mimicking solvent [42] . Figure 2 shows that in a TFE / water mixture 
(50 % v/v), both MH5N and MH5C display a curve, which is characterised by a double 
minimum at 205 and 225 nm and typical of α-helical peptides. Further analysis of these CD 
spectra showed that both peptides were > 60 % α-helical with the remaining structural 
contributions to these peptides coming from random coil and β-type architectures 
(Supplementary data, Table 1).  The outer leaflets of erythrocyte plasma membranes are 
composed mainly of choline lipids, predominantly phosphatidylcholine (PC), which was used 
in the present study as a lipid model for erythrocyte membranes [43]. The conformational 
preferences of MH5N and MH5C in the presence of DMPC were investigated: the resulting 
spectra for both peptides showed negative bands around 222 and 210 nm, indicative of the 
presence of α-helical structure (Figure 2). Analysis of these CD spectra showed that the α-
helical contributions to the structure of MH5N were 42 % whilst those for MH5C were 16 %. 
For both peptides, the remaining contributions to their molecular architecture came from 
random coil and β-type structures (Supplementary data, Table 1).   
 
 
Figure 2. CD structural analysis of maximin H5 isoforms in solvent systems. Figure 2 
shows CD spectra for MH5N (Figure 2A) and MH5C (Figure 2B) in the presence of PBS 
(grey); TFE / water (50 % v / v) (black) and DMPC (dotted black).  Analysis of these spectra 
indicated that in PBS, both peptides were not well folded with a maximum at 212 nm and a 
minimum at 195 nm, which is characteristic of random coil and β-sheet structure (Figure 1A). 
For both MH5C and MH5N, their α-helical content was < 10 % (Supplementary data, Table 
1). In the presence of TFE / water (50 % v / v), both peptides displayed a curve characterised 
by a double minimum at 205 and 225 nm, which is typical of α-helical peptides. Analysis of 
these spectra showed that MH5C and MH5N possessed α-helical contents of > 60 % with the 
remaining structural contributions to their molecular architecture coming from random coil and 
β-type structures (Supplementary data, Table 1). Similarly, in the presence of DMPC, analysis 
of these spectra showed that α-helical contributions to the structures of MH5N and MH5C were 
42 % and 16 % respectively.  
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Lipid monolayer analysis and the lytic ability of maximin H5 isoforms  
The interaction of maximin H5 isoforms with membranes was investigated using monolayers 
formed from DMPC.  Both peptides interacted rapidly with these monolayers, inducing 
maximal surface pressure changes of 7.8 mN m-1 and 10.8 mN m-1 for MH5C and MH5N 
respectively (Figure 3). These surface pressure changes indicate high levels of lipid interaction, 
which are consistent with disruption of the monolayer acyl chain region by maximin H5 and 
imply a major role for hydrophobic forces in driving the membrane interactions of the peptide. 
The interaction of maximin H5 isoforms with membranes was further investigated using large 
unilamellar vesicles (LUVs) formed from DMPC and containing calcein. Both peptides were 
found to possess membranolytic ability that paralleled their interactions with lipid monolayers: 
MH5N and MH5C induced 64 % and 55 % lysis of these LUVs respectively.  
 
Figure 3. The interaction of maximin H5 isoforms with lipid monolayers. Figure 3 shows 
the interaction of MH5N (black) and MH5C (grey) with monolayers formed from DMPC. 
MH5N showed a greater ability to partition into these monolayers than MH5C with these 
peptides inducing maximal surface pressure changes of 10.8 mN m-1 and 7.8 mN m-1, 
respectively.  
 
Molecular dynamic simulations of maximin H5 isoforms 
Molecular dynamic (MD) simulations were used to model and characterize the interaction of 
MH5C and MH5N with membranes formed from DMPC to provide insight into the mechanism 
of membrane partitioning utilized by maximin H5 (Figures 4, 5 and 6). In these simulations, 
three molecules of each peptide were initially orientated parallel to the bilayer and in each case, 
after 20 ns, these three molecules interacted with each other prior to interaction at the bilayer 
surface. Upon interaction with the bilayer surface, each group of three peptides formed an 
aggregate.  This showed a series of changes in its overall levels of secondary structure up to 
200 ns but thereafter showed only very minor changes in this structure up to 400 ns (Figure 
4A). Analysis of snapshots of the aggregates formed by MH5C and MH5N after 400 ns 
(Figures 4A, 4B and 4C) predicted that the secondary structure elements adopted by these 
peptides in the presence of DMPC (Figures 5A and 5B) were generally consistent with those 
determined by CD spectroscopy (Supplementary material Table 1). In the case of MH5N, two 
peptides were predicted to predominantly form unfolded, or β-type structures, but the third was 
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predicted to possess overall levels of α-helicity of circa 40 %. This α-helical structure was 
localized within an N-terminal segment comprising residues I1-S10 of the peptide, and a short 
C-terminal region comprising residues V16-L(NH2)20 (Figures 4A and 4B).  In the case of 
MH5C, two peptide molecules were also predicted to mainly form unfolded, or β-type 
structures, but in contrast to MH5N, the third peptide of MH5C was predicted to possess levels 
of α-helical structure that accounted for only circa 15% of the peptide’s overall structure. This 
α-helical structure predominantly lay in an N-terminal segment, residues I1-V5, and a C-
terminal region, residues V16-L20 (Figure 5A and 5B).  
 
Figure 4. MD simulations of the membrane interaction of maximin H5 isoforms. Figure 4 
shows MD simulations for the interaction of MH5C and MH5N with membranes formed from 
DMPC. In these simulations, three molecules of each peptide were initially orientated parallel 
to the bilayer and upon interaction with the bilayer surface, each group of three peptides formed 
an aggregate and partitioned into the membrane. Each aggregate showed a series of changes in 
its overall levels of secondary structure up to 200 ns but thereafter showed only very minor 
changes in this structure up to 400 ns (Figure 4A). Snapshots of the aggregates formed by these 
peptides after 400 ns showed that MH5N penetrated DMPC membranes more deeply than 
MH5C (Figures 4A and 4B). These figures also showed that the aggregates formed by MH5N 
and MH5C respectively were stabilised by intra-peptide and inter peptide hydrogen bonds 
(Specific examples shown in Figures 6 and 7). MH5C formed no hydrogen bonds with DMPC 
lipids (Figure 4C) but in contrast, MH5N formed multiple hydrogen bonds with these lipids 
(Specific examples shown in Figure 6). However, the C-terminal amide moiety of MH5N 
appeared to form no hydrogen bonds with DMPC lipids. 
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Figure 5. MD predictions for the secondary structures of maximin H5 isoforms. Figures 
5A and 5B show the secondary structure elements predicted for MH5N and MH5C by MD 
simulations. MH5N and MH5C showed levels of α-helicity that were circa 40% and 15% (In 
blue), respectively, which is generally consistent with those determined by CD spectroscopy. 
Partial density profiles were also generated by these MD simulations (Figures 5C and 5D) and 
the graphic in each panel shows partial densities of the components in these peptide-lipid 
systems: overall lipid density (solid black line), lipid head-groups (dots), lipid tails groups 
(dashed line) and peptide (purple line). Essentially, these partial density profiles predicted that 
MH5N (Figure 5C) would penetrate the hydrophobic membrane core region of DMPC 
membranes more deeply than MH5C (Figure 5D). 
 
Partial density profiles were derived from MD simulations and predicted that aggregates of 
MH5C and MH5N respectively (Figure 5C and 5D) would penetrate the hydrophobic core 
region of DMPC membranes.  However, aggregates of MH5N (Figure 5C) showed deeper 
levels of membrane penetration levels than those of the MH5C (Figure 5D). Snapshots of the 
aggregates formed by MH5C and MH5N after 400 ns were further analysed and showed that 
the penetration of DMPC membranes by these aggregates involved a variety of intra–peptide, 
inter-peptide and peptide–lipid hydrogen bonds although via clearly different mechanisms 
(Figures 4, 5 and 6). A major difference between these mechanisms was that MH5C showed 
no peptide-lipid hydrogen bonds in its interaction with DMPC membranes whereas MH5N 
formed multiple hydrogen bonds with lipid head-groups (Figure 6). For example, the L8 
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residue of one unfolded MH5N peptide formed a hydrogen bond with the phosphate group of 
a DMPC lipid whilst the I1 residue of the second unfolded MH5N peptide formed hydrogen 
bonds with the phosphate group of another two DMPC lipids (Figure 6). The L(NH2)20 groups 
of all three MH5N peptides lay near the membrane surface but did not form hydrogen bonds 
with DMPC lipids (Figures 4 and 5).  
 
Figure 6. The peptide-peptide and peptide-lipid interactions of maximin H5 isoforms. 
Figure 6. Aggregates of both MH5C and MH5N were found to form intra-peptide (Figure 7) 
and inter peptide hydrogen bonds (Figure 6A-E). As examples, the V16 residue of one unfolded 
peptide formed a hydrogen bond with G18 of the other unfolded peptide in MH5C aggregates 
(Figure 6A). In the case of MH5N, the I1 residue of one unfolded peptide hydrogen bonded to 
the I1 residue of the other unfolded peptide in these aggregates (Figure 6B). MH5C formed no 
hydrogen bonds with DMPC lipids (Figure 4C) but in contrast, MH5N formed multiple 
hydrogen bonds with these lipids (Figure 6C-E). For example, the I1 residue of an unfolded 
peptide in MH5N aggregates formed hydrogen bonds with the phosphate group of two DMPC 
lipids (Figure 6C). The other unfolded peptide in these aggregates hydrogen bonded to the 
phosphate group of two DMPC lipids via its L8 residue (Figure 6D) and its S10 residue (Figure 
6E). 
 
A second major difference between the interaction of MH5C and MH5N with DMPC 
membranes lay in the role of the α-helical peptide present in the aggregates of both peptides. 
Snapshots of the aggregates formed by MH5N after 400 ns showed that its α-helical peptide 
penetrated the bilayer at an angle of circa 45° in a hairpin-type structure (Figure 4A and 4B). 
One arm of this structure was formed by the N-terminal residues, I1-S10, in a strongly α-helical 
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conformation, whilst the other arm comprised a disordered region, which was terminated by a 
short α-helical segment at the C-terminus of the peptide formed by residues L16-L(NH2)20. 
This oblique orientation of MH5N was stabilised by hydrogen bonds between residues in the 
two α-helical regions of the peptide and phosphate groups in the lipid’s head-group region 
(Figures 4A and 4B). Complementing these peptide-lipid interactions was an intra-peptide 
hydrogen bond between the C-terminal residue, L(NH2)20, of MH5N and its N-terminal 
residue, I1 (Figure 7). The corresponding snapshots of MH5C showed that the peptide 
penetrated DMPC membranes in an orientation and structural conformation that resembled that 
observed for MH5N (Figure 4A and 4C). However, in contrast to MH5N, the α-helical arm of 
the MH5C hairpin was truncated and comprised residues, I1-V5, with the result that the 
disordered region of the juxtaposed arm was elongated before termination by a C-terminal, α-
helical segment formed by residue V16-L20. This oblique orientation of MH5C was primarily 
stabilised by hydrogen bonds between residues in the two α-helical regions of the peptide and 
phosphate groups in the lipid’s head-group region (Figures 4A and 4C). However, in further 
contrast to MH5N, L20 of MH5C was found to be distal from the N-terminal residue, I1, of the 
peptide with no evidence of hydrogen bonding between these two residues (Figure 7).   
 
 
 
Figure 7. C-terminal intra-peptide hydrogen bonding by maximin H5 isoforms. Figure 7A 
and 7B shows MD predictions for the secondary structure of MH5N and MH5C when 
interacting with DMPC membranes, which for clarity are shown in Figures 7C and 7D with the 
lipids removed. These simulations predicted that MH5N would penetrate these membranes at 
an angle of circa 45° in a hairpin-type structure (Figure 7A). One arm of this structure was 
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formed by the N-terminal residues, I1-S10, in a strongly α-helical conformation, whilst the 
other arm comprised a disordered region, which was terminated by a short α-helical segment 
at the C-terminus of the peptide formed by residue L16-L(NH2)20. This overall conformation 
of MH5N was stabilized by a hydrogen bond 4 between its C-terminal residue, L(NH2)20, and 
its N-terminal residue, I1 (4.5 Å, Figure 7C). Corresponding modelling for MH5C predicted 
that the peptide would penetrate the bilayer in an orientation and structural conformation that 
resembled that observed for MH5N (Figure 7B). However, in contrast to MH5N, the α-helical 
arm of the MH5C hairpin was truncated and comprised residues, L1-V5, with the result that 
the disordered region of the juxtaposed arm was elongated before termination by a C-terminal, 
α-helical segment formed by residue V16-L20 (Figures 7D). In further contrast to MH5N, L20 
of MH5C was found to be distal from the N-terminal residue, I1, of the peptide with no 
evidence of H-bonding between these two residues (9.95 Å, Figure 7D).   
 
Discussion 
Maximin H5 is an anionic antibacterial peptide recently identified in the brains and skin 
secretions of the Australian toad, Bombina maxima and it has a narrow spectrum of 
antimicrobial activity having been reported to kill only Staphylococcus aureus [26, 27, 30]. 
These observations give maximin H5 potential interest as a drug for development in the fight 
against methicillin-resistant S. aureus (MRSA), which is currently a major global cause of 
nosocomial and other infections [44]. However, for successful therapeutic application, the 
toxicity of the peptide towards human cells must be characterised and currently, no major 
investigations into this area appear to have been undertaken. Accordingly, here, we have 
investigated the activity of maximin H5 against bacteria and human erythrocytes and 
determined the role of C-terminal amidation in this activity. 
 
Native maximin H5 showed no action against E. coli, confirming previous reports [30].  
However, when modified by C-terminal deamination, the peptide exhibited activity against this 
organism (MIC = 180 µM). This result clearly demonstrates that the resistance of E. coli to the 
action of maximin H5 depends upon the presence of the peptide’s C-terminal amide moiety 
and strongly supports recent work [39]. Using MD simulations, these latter authors predicted 
that H-bonding between the C-terminal amide group of maximin H5 and a lipid receptor in E. 
coli membranes helped immobilize the peptide on the membrane surface, thereby effectively 
rendering the organism resistant to the action of maximin H5 [39]. C-terminally deaminated 
maximin H5 differ from the native peptide in its ability to inactivate S. aureus, exhibiting 
reduced toxicity towards the organism (MIC = 180 µM) as compared to that of maximin H5 
(MIC of 90 µM).  This clearly suggests that the peptide’s C-terminal amide group is required 
for efficient activity against the organism. Indeed, given that this C-terminal amide group, 
along with its N-terminal counterpart, are the only positively charged moieties possessed by 
maximin H5, a likely role for both these amide groups might be to assist in targeting anionic 
components of the membranes possessed by S. aureus [30]. A similar targeting function would 
seem ascribable to the C-terminal amide moiety possessed by a number of isoforms of the 
peptide, which also lack cationic residues and have been identified as potent antibacterial 
agents that function in the brain of B. maxima [26]. It is perhaps worthy of note that a number 
of these latter AMPs were also found to possess anti-noceptive function [26], suggesting that 
maximin H5 and its isoforms may serve as neuropeptides and it is well established that C-
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terminal amidation is essential for the function of many of these neuronal signalling molecules 
[45].   
 
Native maximin H5 was found to possess moderate haemolytic activity (Generally below 25 
%; Figure 1) that was reduced by up to 12 % on C-terminal deamination of the peptide (Figure 
1). Reinforcing these results, native maximin H5 induced dye release of 64 % from DMPC 
vesicles, which were taken as model erythrocyte membranes, however, dye release by the 
peptide was decreased to 55 % in the case of the C-terminally deaminated peptide. In 
combination, these results clearly suggest a role for the C-terminal amide group of maximin 
H5 in the mechanism facilitating the peptide’s haemolytic activity. Investigation into the 
mechanism underpinning the haemolytic activity of native maximin H5 suggested that the 
peptide was able to self-associate and penetrate erythrocyte membranes via the formation of an 
aggregate structure (Figures 4A and 4B). This aggregate associated with the membrane via a 
variety of peptide-lipid hydrogen bonding interactions, which, however, did not involve the C-
terminal amide, L(NH2), groups of the contributing maximin H5 peptides (Figure 4B and 7A). 
Two of the peptides forming these aggregates were unfolded and appeared to play a minor role 
in the membrane interactions of native maximin H5 by stabilising the bilayer penetration of the 
remaining peptide contributing to the aggregate (Figures 4A and 4B). The latter peptide 
appeared to be primarily responsible for membrane penetration by maximin H5 and adopted a 
lipid interactive, hairpin-type conformation whose bilayer partitioning was stabilised by a 
variety of lipid-peptide and intra peptide bonds (Figures 4A, 4B, 6 and 7A). The net negative 
charge carried by maximin H5 results from an internal cluster of D residues, which were distal 
form the membrane surface and appeared to play no direct role in the membrane interactions 
of the peptide (Figures 4B and 7A). Similar observations have previously been reported and it 
has been suggested that these residues primarily served a structural role [39]. The C-terminal 
amide group of maximin H5, L(NH2), hydrogen bonded to the N-terminal residue of the 
peptide, I1, which terminated the major arm of the hairpin structure adopted by maximin H5 
(Figures 7A and 7C). Formed by residues, I1-S10, this sequence adopted an α-helical structure, 
which induced deep insertion of native maximin H5 into membranes at an angle of circa 40° 
(Figures 4B, 5C and 7A). It has previously been shown that residues, I1-S10 forms a tilted 
peptide [46, 47], which is an α-helix with an increasingly asymmetric distribution of 
hydrophobicity along the α-helical long axis that induces membrane penetration at a shallow 
angle between 30° and 60° [48, 49]. However, our investigations also showed that the C-
terminal deamination of maximin H5 removed the ability of its I1 and L20 residues to hydrogen 
bond with each other and caused these residues to move apart from a separation of 4.5 Å to 
9.95 Å (Figure 7), These actions led to lower levels of N-terminal tilted structure in the peptide 
and a decreased ability to penetrate membranes (Figures 4B, 5D and 7B). Taken in 
combination, these observations clearly suggest that a major function of the C-terminal amide 
group of maximin H5 is to stabilise the levels of membrane interactive, oblique orientated α-
helical structure adopted by the peptide in its haemolytic activity. These observations would 
also seem to suggest that hydrophobicity driven interactions make a major contribution to the 
ability of native maximin H5 to penetrate membranes and in this sense, although anionic, the 
peptide resembles many cationic AMPs   [46, 47]. 
 
In summary, the data presented here suggest that the haemolytic ability of native maximin H5 
may render it a poor candidate for therapeutic development. For example, the level of 
haemolysis was 20 % at concentrations of the peptide required to inactivate S. aureus (Figure 
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1). However, when maximin H5 was C-terminally deaminated, although the toxicity of the 
peptide to the latter organism was reduced, its range of target bacteria was broadened.  Also its 
haemolytic activity were significantly decreased, typically 12 % at concentrations of the 
peptide found to inactivate both S. aureus and E. coli (Figure 1). Consistent with previous 
reports [50], these data show that the antimicrobial efficacy and specificity of maximin H5 can 
be attenuated by sequence modification and may assist in the development of variants of the 
peptide with the potential to serve as anti-infectives. The data presented here also suggests that 
the C-terminal amide moiety may play a role in the antimicrobial and cytotoxic activity of 
maximin H5 by the stabilisation of membrane interactive, tilted peptide structure. Indeed, the 
data presented here confirm recent theoretical predictions for maximin H5 [46, 47] and add it 
to the growing number of AMPs that utilise tilted peptide structure to facilitate their membrane 
interactions [3].  
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